PALVELLA THERAPEUTICS, INC. recently released its 10-K report. Palvella is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, focused on developing therapies for serious rare genetic skin diseases and vascular malformations. Its lead candidate is QTORIN 3.9% rapamycin anhydrous gel, which is being studied in Phase 3 for microcystic lymphatic malformations and in Phase 2 for cutaneous venous malformations; the company is also developing QTORIN rapamycin for other mTOR-driven skin diseases.
In Item 7, Management said the company’s operations should be read alongside its audited financial statements and noted that the discussion includes forward-looking statements subject to risks in the Risk Factors section. The filing says “the Company” refers to Legacy Palvella before the merger and to the combined Palvella Therapeutics after the merger completed on December 13, 2024. The business combination was accounted for as a reverse recapitalization under U.S. GAAP, with Pieris treated as the acquired company and Legacy Palvella as the accounting acquirer.
Management described a pipeline centered on the QTORIN platform, which is designed to generate topical product candidates that penetrate deep layers of the skin. QTORIN rapamycin is being developed for microcystic LMs, cutaneous VMs, clinically significant angiokeratomas, and other mTOR-driven skin diseases. In November 2025, the company added QTORIN pitavastatin for disseminated superficial actinic porokeratosis, a disease it says affects more than 50,000 diagnosed patients in the U.S.
For microcystic LMs, the company said the U.S. patient population exceeds 30,000 diagnosed patients. In the Phase 3 SELVA study, 51 participants were enrolled and 50 started treatment; 49 participants aged 6 and older made up the intent-to-treat population. QTORIN rapamycin produced a mean +2.13-point improvement on the mLM-IGA primary endpoint, with 95% of completers showing at least a 1-point improvement and 86% rated “Much Improved” or “Very Much Improved.” The company also said 35 of 50 participants experienced treatment-emergent adverse events, 17 had treatment-related adverse events, and all treatment-related events were mild or moderate.
In the earlier Phase 2 microcystic LM study, 12 subjects received once-daily QTORIN rapamycin for 12 weeks, and all participants improved on the Clinician Global Impression of Change scale; 7 were rated “Much Improved” and 5 were rated “Very Much Improved.” The company said it submitted a pre-NDA meeting request to the FDA in the first quarter of 2026 and expected the meeting in the second quarter of 2026. It also said QTORIN rapamycin has Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, plus Orphan Drug Designation from the European Medicines Agency, and that it received up to $2.6 million in FDA clinical trial grant support, including $0.5 million in May 2025 and $0.6 million in October 2025.
For cutaneous VMs, management estimated more than 75,000 diagnosed patients in the U.S. The Phase 2 TOIVA study enrolled 16 participants and showed nominal statistical significance on multiple pre-specified endpoints at Week 12, including the Overall cVM-IGA, where 73% of participants improved and 67% were rated “Much Improved” or “Very Much Improved.” The company said treatment-related adverse events were mild or moderate, with application-site erythema the most common treatment-emergent adverse event at 25%. It plans to submit a Breakthrough Therapy Designation application in the second quarter of 2026 and to begin a Phase 3 pivotal study in the second half of 2026.
The company also expanded QTORIN rapamycin into clinically significant angiokeratomas, which it said affect more than 50,000 diagnosed patients in the U.S. It received FDA feedback on a proposed Phase 2 study of about 10 to 20 patients and expects to start that trial in the second quarter of 2026. For DSAP, the company said it received FDA feedback on a proposed Phase 2 study and expects to initiate the trial in the second half of 2026.
The filing also detailed the December 13, 2024 merger with Pieris Pharmaceuticals. At closing, Merger Sub merged into Legacy Palvella, Legacy Palvella survived as a wholly owned subsidiary, and the company changed its name to Palvella Therapeutics, Inc. Concurrently, PIPE investors purchased 3,168,048 shares of common stock and pre-funded warrants exercisable for 2,466,456 shares of common stock at a purchase price of $13.9965 per share. The market has reacted to these announcements by moving the company's shares -2.31% to a price of $117.61. For the full picture, make sure to review PALVELLA THERAPEUTICS, INC.'s 10-K report.
